Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
25
Recruiting, any sponsor type, condition "gastroesophageal reflux disease"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed360
25 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksPivotal-lookingRecruiting
Phathom Pharmaceuticals, Inc.Industry
NCT07752407 · 500 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 20, 2027
Drug: Vonoprazan; Placebo · For: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Sites: Phoenix, Arizona; Chula Vista, California; Lomita, California · 26 sites in all
- PPI Dosing Per CYP2C19 GenotypePivotal-lookingRecruiting
University of FloridaAcademic, hospital or other
NCT07843264 · 200 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 31, 2027
Drug: CYP2C19 based dosing Proton Pump Inhibitors; Conventional proton pump inhibitor dose · For: Gastroesophageal Reflux Disease With Esophagitis
Sites: Jacksonville, Florida
BayerBayer (BAYRY)
NCT07291700 · 167 participants (planned) · Start Nov 18, 2025 · Primary completion Oct 31, 2027
Drug: Hydrotalcite (Talcid, BAYX002833) · For: Gastroesophageal Reflux
Sites: Multiple Locations, Germany
- Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan CitrateRecruiting
Jeil Pharmaceutical Co., Ltd.Industry
NCT07894939 · 3,000 participants (planned) · Start Nov 2, 2024 · Primary completion Dec 31, 2029
Drug: zastaprazan citrate · For: Erosive Gastroesophageal Reflux Disease
Sites: Seoul, South Korea
Phathom Pharmaceuticals, Inc.Industry
NCT06660342 · 728 participants (planned) · Start May 15, 2025 · Primary completion Sep 2034
Drug: Vonoprazan · For: Erosive Esophagitis; Heartburn; Symptomatic Non-erosive Gastroesophageal Reflux Disease and 1 more
Sites: Wilmington, North Carolina
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme ReductionPivotal-lookingRecruiting
Medical College of WisconsinAcademic, hospital or other
NCT04383262 · 104 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 1, 2027
Drug: Fosamprenavir Calcium · For: Laryngopharyngeal Reflux
Sites: Milwaukee, Wisconsin
- Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.Pivotal-lookingRecruiting
Hualien Tzu Chi General HospitalAcademic, hospital or other
NCT06778824 · 610 participants (planned) · Start Apr 2, 2024 · Primary completion Dec 31, 2026
Drug: Takepron; Zoloft 50Mg Tablet and 1 more · For: Gut-Brain Disorders; GERD Without Erosive Esophagitis
Sites: Hualien City, Taiwan
- Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux DiseasePivotal-lookingRecruiting
Devintec SaglIndustry
NCT06984484 · 208 participants (planned) · Start Jul 2, 2025 · Primary completion Jan 2027
Drug: Placebo · For: Gastroesophageal Reflux Disease (GERD)
Sites: Genova, Italy; Milan, Italy; Naples, Italy · 7 sites in all
Minia UniversityAcademic, hospital or other
NCT07750379 · 60 participants (planned) · Start Apr 28, 2026 · Primary completion Dec 30, 2026
Drug: PPI · For: Laryngomalacia
Sites: Minya, Egypt
- Gastrointestinal Dysmotility on Aspiration RiskPivotal-lookingRecruiting
Boston Children's HospitalAcademic, hospital or other
NCT05455359 · 120 participants (planned) · Start Feb 13, 2025 · Primary completion May 31, 2027
Drug: Prucalopride; Famotidine · For: Esophageal Motility Disorders; Gastric Motor Dysfunction; Aspiration Pneumonia and 1 more
Sites: Boston, Massachusetts
- A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan GluratePivotal-lookingRecruiting
Cinclus Pharma Holding ABIndustry
NCT05469854 · 121 participants (planned) · Start Jul 13, 2022 · Primary completion Nov 30, 2026
Drug: Linaprazan glurate; Placebo · For: Pharmacokinetics; Cardiodynamic ECG; Safety, and Tolerability and 1 more
Sites: Uppsala, Sweden
Stony Brook UniversityAcademic, hospital or other
NCT06241183 · 80 participants (planned) · Start Nov 9, 2023 · Primary completion Dec 31, 2027
Drug: Intravenous Famotidine; Oral Maalox/ Mylanta · For: Dyspepsia; GERD; Acid Reflux
Sites: Stony Brook, New York
- Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEMPivotal-lookingRecruiting
Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
NCT06955520 · 300 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 10, 2027
Drug: Vonoprazan; Esomeprazole 40mg · For: GERD
Sites: Hyderabad, India
Jose CocjinAcademic, hospital or other
NCT04699591 · 20 participants (planned) · Start Apr 2013 · Primary completion Dec 2035
Drug: Domperidone · For: GERD; Gastroesophageal Reflux; Gastroparesis
Sites: Kansas City, Missouri
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 WeeksPivotal-lookingRecruiting
Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
NCT06953986 · 414 participants (planned) · Start Dec 20, 2025 · Primary completion Nov 20, 2026
Drug: Vonoprazan; Esomeprazole 40mg · For: GERD
Sites: Hyderabad, India
Valenta Pharm JSCIndustry
NCT07421011 · 36 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2026
Drug: Trimedat® · For: Irritable Bowel Syndrome; Gallstone Disease; GERD and 2 more
Sites: Saint Petersburg, Russia
- Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal AchalasiaPivotal-lookingRecruiting
Centre Hospitalier Universitaire de NīmesAcademic, hospital or other
NCT05899842 · 132 participants (planned) · Start Jun 1, 2023 · Primary completion Feb 2028
Drug: Protein pump inhibitor therapy systematically · For: Esophageal Achalasia
Sites: Marseille, France; Montpellier, France; Nîmes, France · 4 sites in all
- Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic CoughRecruiting
Mayo ClinicAcademic, hospital or other
NCT05110144 · 50 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 2026
Drug: Duloxetine 30 MG; Duloxetine 60 MG and 4 more · For: Refractory Chronic Cough
Sites: Rochester, Minnesota
- Heartburn, Gastroesophageal Reflux DiseasePivotal-lookingRecruiting
Incheon St.Mary's HospitalAcademic, hospital or other
NCT07268820 · 160 participants (planned) · Start Jul 7, 2025 · Primary completion May 29, 2026
Drug: Zastaprazan; Esomeprazole · For: GERD
Sites: Ansan, South Korea; Busan, South Korea; Chilgok, South Korea · 10 sites in all
Odense University HospitalAcademic, hospital or other
NCT06255886 · 96 participants (planned) · Start Oct 27, 2025 · Primary completion Dec 26, 2026
Drug: Protein pump inhibitor.; Placebo · For: Gastroesophageal Reflux; Infant, Newborn, Diseases
Sites: Aabenraa, Denmark; Odense, Denmark · 3 sites in all
- Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease SymptomsPivotal-lookingRecruiting
Adnan Imtiaj RahulAcademic, hospital or other
NCT07063576 · 60 participants (planned) · Start Aug 1, 2025 · Primary completion Jul 2026
Drug: Baclofen 10mg; Placebo · For: GERD - PPI Non-responders
Sites: Dhaka, Bangladesh
- The Mechanism Versus PPI TrialPivotal-lookingRecruiting
University of California, San DiegoAcademic, hospital or other
NCT06999577 · 160 participants (planned) · Start Jun 4, 2025 · Primary completion May 1, 2029
Drug: Omeprazole 40 MG · For: Laryngopharyngeal Reflux; Cough; Throat Clearing and 2 more
Sites: San Deigo, California
- Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or PantoprazolePivotal-lookingRecruiting
Carnot LaboratoriesIndustry
NCT06991348 · 128 participants (planned) · Start Jul 30, 2024 · Primary completion Nov 30, 2025
Drug: Tegoprazan; Pantoprazole · For: Gastroesophageal Reflux Disease
Sites: Mexico City, Mexico; Boca del Río, Mexico
Shanghai Hutchison Pharmaceuticals LimitedIndustry
NCT06755671 · 4,500 participants (planned) · Start Apr 30, 2025 · Primary completion Jun 30, 2027
Drug: Danning Tablet · For: Indigestion; Dyspepsia; Bloating and 5 more
Sites: Hangzhou, China
Tanta UniversityAcademic, hospital or other
NCT06564246 · 44 participants (planned) · Start Sep 18, 2024 · Primary completion Aug 2026
Drug: Vonoprazan 20 mg versus Pantoprazole 40 mg · For: Gastroesophageal Reflux Disease (GERD)
Sites: Giza, Egypt
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.